Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

DT Blumenthal; T Gorlia; MR Gilbert; MM Kim; LB Nabors; WP Mason; ME Hegi; PX Zhang; V Golfinopoulos; JR Perry; DH Nam; SC Erridge; BW Corn; RO Mirimanoff; PD Brown; BG Baumert; MP Mehta; Martin van den Bent; DA Reardon; M Weller; R Stupp

doi:10.1093/neuonc/nox025

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

DT Blumenthal, T Gorlia, MR Gilbert, MM Kim, LB Nabors, WP Mason, ME Hegi, PX Zhang, V Golfinopoulos, JR Perry, DH Nam, SC Erridge, BW Corn, RO Mirimanoff, PD Brown, BG Baumert, MP Mehta, Martin van den Bent, DA Reardon, M WellerR Stupp

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

88 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1119-1126
Number of pages	8
Journal	Neuro-Oncology
Volume	19
Issue number	8
DOIs	https://doi.org/10.1093/neuonc/nox025
Publication status	Published - 2017

Access to Document

10.1093/neuonc/nox025

http://hdl.handle.net/1765/108427

Cite this

Blumenthal, DT., Gorlia, T., Gilbert, MR., Kim, MM., Nabors, LB., Mason, WP., Hegi, ME., Zhang, PX., Golfinopoulos, V., Perry, JR., Nam, DH., Erridge, SC., Corn, BW., Mirimanoff, RO., Brown, PD., Baumert, BG., Mehta, MP., van den Bent, M., Reardon, DA., ... Stupp, R. (2017). Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-Oncology, 19(8), 1119-1126. https://doi.org/10.1093/neuonc/nox025

@article{d67f2fe1cdd84d2b90cd3e5fd8433330,

title = "Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG",

author = "DT Blumenthal and T Gorlia and MR Gilbert and MM Kim and LB Nabors and WP Mason and ME Hegi and PX Zhang and V Golfinopoulos and JR Perry and DH Nam and SC Erridge and BW Corn and RO Mirimanoff and PD Brown and BG Baumert and MP Mehta and {van den Bent}, Martin and DA Reardon and M Weller and R Stupp",

year = "2017",

doi = "10.1093/neuonc/nox025",

language = "Undefined/Unknown",

volume = "19",

pages = "1119--1126",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "8",

}

Blumenthal, DT, Gorlia, T, Gilbert, MR, Kim, MM, Nabors, LB, Mason, WP, Hegi, ME, Zhang, PX, Golfinopoulos, V, Perry, JR, Nam, DH, Erridge, SC, Corn, BW, Mirimanoff, RO, Brown, PD, Baumert, BG, Mehta, MP, van den Bent, M, Reardon, DA, Weller, M & Stupp, R 2017, 'Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG', Neuro-Oncology, vol. 19, no. 8, pp. 1119-1126. https://doi.org/10.1093/neuonc/nox025

TY - JOUR

T1 - Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

AU - Blumenthal, DT

AU - Gorlia, T

AU - Gilbert, MR

AU - Kim, MM

AU - Nabors, LB

AU - Mason, WP

AU - Hegi, ME

AU - Zhang, PX

AU - Golfinopoulos, V

AU - Perry, JR

AU - Nam, DH

AU - Erridge, SC

AU - Corn, BW

AU - Mirimanoff, RO

AU - Brown, PD

AU - Baumert, BG

AU - Mehta, MP

AU - van den Bent, Martin

AU - Reardon, DA

AU - Weller, M

AU - Stupp, R

PY - 2017

Y1 - 2017

U2 - 10.1093/neuonc/nox025

DO - 10.1093/neuonc/nox025

M3 - Article

SN - 1522-8517

VL - 19

SP - 1119

EP - 1126

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 8

ER -